We report two cases of hyperkalaemia related to the use of the salt substitute 'Lo Salt' in hypertensive patients on treatment with ACE inhibitors. In each case serum potassium returned to the normal range after cessation
Introduction
ACE inhibitors are an important class of pharmacological agents in the management of hypertension and heart failure. They may however cause hyperkalaemia due to simultaneous use of potassium sparing diuretics or potassium supplements, as well as in patients with renal failure. Hypertensive patients are usually given advice about reducing dietary salt intake. They may try to achieve this through the use of salt substitutes, the sale of which is unsupervised in the United Kingdom. We report two cases where salt substitutes caused severe hyperkalaemia.
Case 1
A 67-year-old Afro-Caribbean man presented with an episode of loss of consciousness. There was no associated motor deficit, nor were there any symptoms suggestive of epilepsy. There was a 3-day history of dizziness and intermittent vomiting, as a result of which he had drunk very little and become lethargic and unable to self care.
His past medical history included hypertension, coronary artery bypass surgery and left ventricular dysfunction. His medication at admission was atenolol 100 mg daily, frusemide 40 mg daily, aspirin 75 mg daily and lisinopril 20 mg daily. Due to inadequate control of his hypertension, the dose of lisinopril had been increased 12 days prior to admission from 10 mg daily.
Examination was unremarkable apart from a resting sinus bradycardia, which was initially attri- buted to beta blockade. Whilst in casualty he had three further episodes of vomiting. A resting electrocardiogram showed slightly peaked T-waves in leads V 1 -V 3 and T-wave inversion in leads l, aVL and V 4 -V 6 ( Figure 1 ). Serum biochemistry was markedly deranged with a serum potassium of 7.6 mMol/l, a urea of 12.3 mMol/l and a creatinine of 159 Mol/l (normal range 44 -133 Mol/l).
Hyperkalaemia was confirmed on a repeat blood sample, and he was commenced on 15 units of insulin (actrapid) in 50 ml of 50% dextrose, over 30 minutes. Shortly afterwards he became hypotensive with a blood pressure of 50/30 mm Hg and a pulse of 25 beats per minute. An electrocardiogram done at that time showed marked sinus bradycardia ( Figure 2 ). He had a brief cardiac arrest which was attributed to bradycardia. Following the administration of 600 g of atropine his pulse rose to 70 beats per minute, with a blood pressure of 108/80 mm Hg.
He was given a further dose of insulin and dextrose (50 units actrapid in 50 ml of 50% dextrose) as well as 45 g of calcium resonium per day. An intravenous infusion of 5% dextrose-saline was commenced as he was clinically dehydrated. The lisinopril and frusemide were stopped. Repeat serum potassium 1 h later was 6.5 mMol/l.
An initial diagnosis of hyperkalaemia secondary to ACE inhibition was made. However upon reviewing his case notes it appeared that he had been taking lisinopril for 1 year and had been on 10 mg per day for at least 9 months. Upon questioning the patient regarding the use of non-proprietary medications, it appeared that our patient had been using the salt substitute 'Lo Salt' for 1 week prior to admission. Every 100 g of 'Lo Salt' contains 34.6 g of potassium. A detailed dietary history suggested a diet which was already high in potassium, with a high intake of fruit, vegetables, fruit juice and wholemeal bread. In addition he appeared to be adding 70 mMol of potassium per day in the form of 'Lo Salt'. Despite clear instructions on the packet of potential interactions with cardiovascular drugs, our patient was unaware of any potential hazard.
The cause of the hyperkalaemia was the interaction between 'Lo Salt' and lisinopril. The dizziness and vomiting prior to admission may also have been attributable to hyperkalaemia. The vomiting in turn caused dehydration leading to the rise in urea and creatinine levels.
Following rehydration and the cessation of the ACE inhibitor and diuretics the serum chemistry returned to normal with a urea of 5.7 mMol/l, creatinine of 113 Mol/l and a potassium of 4.4 mMol/l. Our patient was discharged home on frusemide, aspirin and atenolol, with plans to reintroduce lisinopril later. He was told to abstain from using 'Lo Salt'.
Case 2
A 64-year-old Afro-Caribbean man with a 24-year history of diabetes mellitus and isolated systolic hypertension for 3 years, was found to have proteinuria at out-patient review. He had a number of other sequelae of long standing diabetes, in the form of retinopathy which had required laser treatment and also renal impairment.
His blood pressure in clinic was 168/93 mm Hg and his urea was 15.2 mMol/l with a creatinine of 196 Mol/l and a serum potassium of 5 mMol/l. He was given dietary advice about salt restriction and enalapril was commenced at a dose of 2.5 mg twice daily. His blood pressure responded well to ACE inhibition and came down to 144/78 mm Hg. A repeat of his urea and electrolytes 4 months later were found to be deranged with a serum potassium of 7 mMol/l, a urea of 12.8 mMol/l and a creatinine of 181 Mol/l.
We explained to our patient that he needed to be admitted because one of his salts was too high, at which point he replied: 'it can't be because I am taking Lo Salt'. The hyperkalaemia was corrected using insulin and dextrose as already described and then calcium resonium 45 g per day for 48 h. The ACE inhibitor was stopped temporarily. Until our patient mentioned that he was taking 'Lo Salt', it was felt that the most likely cause of hyperkalaemia was the ACE inhibitor alone. Dietary review showed that his normal potassium intake was 70 mMol per day. In addition he was taking 133 mMol of potassium in the form of 'Lo Salt'. The normal requirement for a man of his age is around 90 mMol of potassium per day. Enalapril was reintroduced and 'Lo Salt' stopped. His electrolytes remained stable with a urea of 14 mMol/l, creatinine of 191 Mol/l and a potassium of 5.7 mMol/l, 2 months later.
Discussion
The contribution of dietary sodium intake to the pathogenesis of hypertension is well known. 1 Patients with hypertension are conventionally given dietary advice on the reduction of salt intake. Many patients seek salt substitutes such as 'Lo Salt' to aid their diet. This in itself is not harmful but clinicians treating hypertension must be aware of potential interactions between ACE inhibitors and salt substitutes, particularly when giving dietary advice.
ACE inhibitors are an effective treatment for hypertension. In addition certain groups of patients appear to have prognostic benefits as well as a reduction in morbidity. These include patients with heart failure, 2-4 diabetic nephropathy 5 and diabetic retinopathy. 6 There are potential dangers however. ACE inhibitors may lead to a reversible deterioration in renal function and hyperkalaemia. 7 There are potential interactions with either potassium sparing diuretics or fixed combination proprietary diuretics, which may lead to life threatening arrhythmias. 8 If potassium supplements are used in conjunction with ACE inhibitors, then careful monitoring of serum potassium is recommended. 9 In patients whose renal blood flow becomes increasingly dependent on angiotensin II and prostaglandins, acute renal failure has been attributed to the concomitant use of ACE inhibitors with non-steroidal anti-inflammatory drugs (NSAIDS). 10 Patients with suppressed renin-angiotensin system activity are more prone to the risks of hyperkalaemia. This particularly applies to Afro-Caribbean patients and diabetics, who have hyporeninaemic hypoaldosteronism. ACE inhibitors are safe to use in these groups, but vigilance is imperative if nephrotoxic drugs are co-administered or an additional potassium load added and this includes the use of the salt substitute 'Lo Salt'.
'Lo salt' has been implicated in a cardiac arrest secondary to hyperkalaemia in a patient also taking the NSAID, nabumetone. 11 We believe that the two cases shown, including one of life threatening arrhythmia, are the first reports in the literature of the potential harmful interaction between 'Lo salt' and ACE inhibitors. In both cases hyperkalaemia was initially attributed to ACE inhibitors and this would have led to the indefinite withdrawal of ACE inhibitors in groups of patients in whom ACE inhibition has been shown to be beneficial, ie, heart failure and diabetic nephropathy. In case 1, vigilance lead to the identification of 'Lo Salt' in the diet and in case 2 luck played a hand.
'Lo Salt' is available in any supermarket and there are no regulations governing its purchase, unlike 'over the counter drugs' sold in pharmacies. The container has a 'logo' which states, 'use as ordinary cooking and table salt, with 66% less sodium than common salt.' 'Lo Salt' contains 34.6 g of potassium for every 100 g of 'Lo Salt'. Containers of 'Lo Salt' clearly have a health warning of potential interactions with cardiovascular and diabetic drugs. It reads: 'it is suggested that people receiving medication for diabetes, heart or kidney disorders should consult their family doctor who will advise on how to use this salt alternative'. However as the product is available without regulation, many customers may be unaware of its potential dangers.
Tubs of 'Lo Salt' state that: 'medical evidence suggests that excessive sodium in the diet may aggravate a high blood pressure (hypertension) problem'. 'For the health conscious person it is now possible to season food as usual while reducing sodium intake because Lo Salt is high in natural potassium and low in sodium salt. ' In an age where we encourage healthy eating, the use of salt substitutes may well increase. It may be therefore prudent to restrict the sale of salt substitutes to pharmacies, where some degree of supervision and advice is possible. Also when hypertensive patients are given dietary advice, this should include advice on avoiding salt substitutes when potential interactions with ACE inhibitors or angiotensin II receptor antagonists may occur. Finally, in patients presenting with hyperkalaemia, a dietary history is mandatory to exclude the use of salt substitutes.
